Latest Study Finds Chloroquine Increases Risk of Death in COVID-19 Patients.
Two observational studies, published in the “New England journal of Medicine” and the “Journal of the Americal Medical Association” found that among thousands of hospitalized corona virus patients, those who received the antimalarial medication hydroxychloroquine didn’t fare better or worse than patients who didn’t receive this drug.
More evidence found that the antimalarial medications touted by President Donald Trump aren’t a good bet for treating the coronavirus.
A new study found that the treatments didn’t appear to help patients hospitalized with the novel coronavirus and instead were associated with heart complications and an increased risk of death.
This analysis looked at the hospital outcomes of 96,032 hospitalized patients, 14,888 of whom got some form of the antimalarial treatments chloroquine and hydroxychloroquine over the course of 4 months.
The patients came from 671 hospitals from 6 continents, and the study was led by researchers at the Brigham and Women’s Hospital in Boston.
It examined the outcome of patients who were treated with hydroxychloroquine, hydroxychloroquine and a macrolide antibiotic, chloroquine, or chloroquine and a macrolide antibiotic. Macrolides are a type of antibiotic that includes azithromycin.
Ultimately, they couldn’t find a benefit in those who were given the treatments compared with those who didn’t receive any of the combinations. Instead, the study found an increased frequency in abnormal heartbeats in those who received the medicines.
Those who received the medicines had a higher risk of death compared with those who did not take the medications.
The drug caught the eyes of doctors, experts, and the Trump administration as a potential coronavirus treatment early in the pandemic,
President Donald Trump recently said that he had been taking hydroxychloroquine every day for a week and a half.
The drug has not been approved by the US Food and Drug Administration for the treatment of COVID-19.